Cover Image
市場調查報告書

C-C細胞因子受體5:開發中產品分析

C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363124
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
C-C細胞因子受體5:開發中產品分析 C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 77 Pages
簡介

本報告提供C-C細胞因子受體5藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

C-C細胞因子受體5概要

治療藥的開發

C-C細胞因子受體5:開發中的產品 - 各開發階段

C-C細胞因子受體5:開發中的產品 - 治療範圍別

C-C細胞因子受體5:開發中的產品 - 各適應症

C-C細胞因子受體5:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

C-C細胞因子受體5:企業開發中的產品

C-C細胞因子受體5:大學/機關開發中的產品

C-C細胞因子受體5:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

C-C細胞因子受體5治療藥的開發企業

  • American Gene Technologies International Inc.
  • ChemoCentryx, Inc.
  • Cytodyn Inc.
  • GlaxoSmithKline Plc
  • NeED Pharma s.r.l.
  • Pharis Biotec GmbH
  • Tobira Therapeutics, Inc.

C-C細胞因子受體5:藥物簡介

C-C細胞因子受體5:暫停中的計劃

C-C細胞因子受體5:中止開發的產品

C-C細胞因子受體5:主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0082TDB

Summary

Global Markets Direct's, 'C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016', provides in depth analysis on C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5)
  • The report reviews C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) Overview
  • Therapeutics Development
    • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Stage of Development
    • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Therapy Area
    • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Indication
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Companies
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Universities/Institutes
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
    • American Gene Technologies International Inc.
    • ChemoCentryx, Inc.
    • Cytodyn Inc.
    • GlaxoSmithKline Plc
    • NeED Pharma s.r.l.
    • Pharis Biotec GmbH
    • Tobira Therapeutics, Inc.
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
    • (cenicriviroc mesylate + efavirenz + lamivudine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (cenicriviroc mesylate + lamivudine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-1105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAL-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAL-MGMT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAL-X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCL-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenicriviroc mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-214096 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-4043 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRO-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RAP-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Dormant Projects
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
  • C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Featured News & Press Releases
    • May 16, 2016: Clinical Abstract from CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Now Available on ASM Microbe 2016 Conference Website
    • May 13, 2016: Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients
    • May 03, 2016: CytoDyn's Compassionate Use Protocol Receives FDA Clearance to Proceed
    • May 02, 2016: Tobira Announces Interim 12-week Results from the ORION Study
    • Apr 14, 2016: CytoDyn Files a Compassionate Use Protocol With FDA
    • Mar 09, 2016: Tobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials
    • Feb 09, 2016: Tobira Therapeutics Completes Patient Recruitment for ORION Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease
    • Jan 28, 2016: CytoDyn Reports Full Virologic Suppression in Eleven HIV Patients on PRO 140 Monotherapy for Up to 17 Months
    • Jan 22, 2016: CytoDyn Files Request for Breakthrough Therapy Designation With the FDA for Use of PRO 140 in HIV Therapy
    • Jan 20, 2016: CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
    • Jan 19, 2016: CytoDyn Announces HIV-Patients Approaching 17 Months of Complete Viral Suppression With PRO 140 Monotherapy
    • Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis
    • Dec 22, 2015: CytoDyn Files for Orphan Drug Designation for Use of PRO 140 in Graft Versus Host Disease
    • Dec 21, 2015: FDA Clears CytoDyn for Relaxed Entry Criteria for Its Ongoing Phase 3 Trial in HIV-Infected Patients
    • Dec 14, 2015: CytoDyn Receives FDA Clearance for Its First Non-HIV Indication for PRO 140
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by American Gene Technologies International Inc., H1 2016
  • Pipeline by ChemoCentryx, Inc., H1 2016
  • Pipeline by Cytodyn Inc., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by NeED Pharma s.r.l., H1 2016
  • Pipeline by Pharis Biotec GmbH, H1 2016
  • Pipeline by Tobira Therapeutics, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top